An Investor Asks… What’s the Status of the Collaboration wit∙∙∙

Korea’s First Radiopharmaceutical Nears Commercialization… W∙∙∙

First-Generation Biotech Strength… Laying the Foundation for∙∙∙

Cellbion Advances Toward Commercialization of Its Prostate C∙∙∙

Cellbion Initiates First Patient Dosing This Month in RPT–Ke∙∙∙

Cellbion Accelerates Early Supply Chain Development as Korea∙∙∙

Cellbion Submits Application to MFDS for Conditional Approva∙∙∙

“Can Cellbion Disrupt Pluvicto’s Monopoly?” — Targeting KRW ∙∙∙

Cellbion’s Prostate Cancer RPT Shows Strong Prospects for Co∙∙∙

Cellbion Nears Commercialization of Prostate Cancer Therapy,∙∙∙

Cellbion’s Preclinical Study of ‘225Ac-RPT’ for Prostate Can∙∙∙

“Decisive December”: Cellbion Nears Korea’s First Commercial∙∙∙

Cellbion Signs an Agreement with the Korea Pasteur Institute∙∙∙

“From Diagnosis to Treatment” — Radiopharmaceuticals Open a ∙∙∙

Kim Kwon, CEO of Cellbion: “We will deliver a success case i∙∙∙

Cellbion Signs Agreement with Dongnam Institute of Radiologi∙∙∙

“Data-Driven Competitiveness in Asia—Now Expanding Toward Gl∙∙∙

Estimated Market Share of 7.4%: Roadmap for Stepwise Product∙∙∙

Accelerated Commercialization Strategy With Regulatory Submi∙∙∙

Cellbion Partners with Institut Pasteur Korea to Break Groun∙∙∙